Clinical Trials Logo

Neoplasm Metastases clinical trials

View clinical trials related to Neoplasm Metastases.

Filter by:

NCT ID: NCT01336985 Terminated - Melanoma Clinical Trials

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

Start date: March 28, 2011
Phase: Phase 1
Study type: Interventional

Background: - Cancers in other parts of the body often spread to the liver, developing tumors which in many instances cannot be removed with surgery. Liver chemoembolization is a treatment that is routinely performed to control liver tumors in those who cannot have surgery. It has been shown to prolong survival, but does not cure the cancer. During chemoembolization very tiny beads (drug-eluting beads, or DEB) containing chemotherapy drugs (usually doxorubicin) are administered directly into the blood vessels of a liver tumor. The drug within the beads is then released into the tumor whilethe beads temporarily interrupt the tumor s blood supply. - Irinotecan, a drug commonly given intravenously to treat colon cancer, has been given in chemoembolization procedures in four other studies that have shown that the treatment is generally well tolerated. Researchers are interested in determining whether giving the drug irinotecan directly into the liver using drug-eluting beads is not only well tolerated but also provides a larger dose directly to the tumor as determined by tumor and normal liver tissue biopsies. The liver biopsies are an optional portion of the study. Objectives: - To evaluate the safety and effectiveness of chemoembolization with irinotecan for tumors caused by cancer that has spread to the liver. Eligibility: - Individuals at least 18 years of age who have melanoma, colon, or another intra-abdominal cancer that has spread to the liver. Design: - Participants will be screened with a physical examination, medical history, blood tests, tumor imaging studies, and liver biopsies. - Participants will receive up to 3 DEB chemoembolization treatments about 6 weeks apart. - After two treatments, participants will have imaging studies to see if the tumors have shrunk, and those whose tumors have shrunk may have a third treatment. - Multiple liver biopsies may be performed and blood samples will be taken to determine how much drug is in the tumor and the circulation, and to see how the tumor reacts to the drug. - Participants will return for followup visits for up to 1 year....

NCT ID: NCT01273493 Completed - Clinical trials for Hepatic Insufficiency

A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.

NCT ID: NCT01273480 Completed - Neoplasm Metastases Clinical Trials

A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Start date: December 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.

NCT ID: NCT01267084 Completed - Neoplasm Metastases Clinical Trials

A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies

Start date: February 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the potential effects of ketoconazole on blood levels of trabectedin after administration to patients with advanced malignancies.

NCT ID: NCT01122199 Completed - Neoplasm Metastases Clinical Trials

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors

Start date: May 14, 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.

NCT ID: NCT00668382 Completed - Neoplasm Metastases Clinical Trials

Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection

Start date: July 2007
Phase: Phase 1
Study type: Interventional

This is a Phase I pilot study to evaluate the toxicity and feasibility of intratumoral injection (Glycosphingolipids) GSL alpha-GAL (beta-galactosidase) in patients with advanced, refractory solid tumors who have failed standard therapies or are not eligible for standard treatment.

NCT ID: NCT00556049 Completed - Clinical trials for Renal Cell Carcinoma

Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine if the combination of sunitinib and gemcitabine is effective in treating patients with metastatic renal cell carcinoma. The safety of this combination will also be studied. Sunitinib is approved by the FDA for the treatment of renal cell carcinoma. However, some patients' cancers do not respond to treatment or stops responding after initially responding. Gemcitabine is a chemotherapy drug that is approved by the FDA for the treatment of pancreatic cancer and several other cancers. It is not approved for the treatment of renal cell carcinoma. Previous research has suggested that combining gemcitabine with sunitinib may have some effectiveness in treating metastatic renal cell carcinoma.

NCT ID: NCT00184353 Completed - Neoplasm Metastases Clinical Trials

Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T.

Start date: November 2003
Phase: N/A
Study type: Observational

Increasing magnetic field is known to give improvements in signal-to-noise-ratio (SNR) and spectral resolution. To investigate this, spectra from different subjects were examined using two clinical MR instruments operating at 1.5T and 3T respectively.

NCT ID: NCT00152906 Completed - Liver Neoplasms Clinical Trials

Stereotactic Radiotherapy (SRT) Liver (COLD 1)

Start date: July 2003
Phase: Phase 1/Phase 2
Study type: Interventional

A minority of patients with colorectal liver metastases and hepatobiliary cancer (primary liver cancer) are candidates for surgery, but there are no curative treatment options for these patients. Their median survival time is 3 to 12 months. Stereotactic radiation (SRT) (highly conformal radiotherapy (CRT)) is a treatment option for these patients with unresectable liver cancer, now possible due to improvements in our ability to localize and immobilize liver tumors and an improved understanding of the partial liver volume tolerance to radiation. SRT should permit liver tumors to be treated to tumorcidal doses while sparing the uninvolved liver, decreasing the risk of treatment related normal tissue toxicity. With such conformal radiation, it is possible to deliver radiation in fewer fractions than traditionally required, which should be more convenient for patients. In this study, CRT will be delivered during shallow breathing or breath hold to minimize organ motion due to breathing, decreasing the volume of normal liver that must be irradiated.